MRNA

Company Overview — What Does Moderna, Inc. Do?

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna, Inc. (MRNA) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Stéphane Bancel and employs approximately 3,900 people. With a market capitalization of $19.8B, MRNA is one of the prominent companies in the Healthcare sector.

Moderna, Inc. (MRNA) Stock Rating — Hold (April 2026)

As of April 2026, Moderna, Inc. receives a Hold rating with a composite score of 42.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.MRNA ranks #1,966 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Moderna, Inc. ranks #207 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MRNA Stock Price and 52-Week Range

Moderna, Inc. (MRNA) currently trades at $51.04. The stock lost $0.24 (0.5%) in the most recent trading session. The 52-week high for MRNA is $59.55, which means the stock is currently trading -14.3% from its annual peak. The 52-week low is $22.28, putting the stock 129.1% above its annual trough. Recent trading volume was 6.3M shares, reflecting moderate market activity.

Is MRNA Overvalued or Undervalued? — Valuation Analysis

Moderna, Inc. (MRNA) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.30x, versus the sector average of 2.75x. The price-to-sales ratio is 6.35x, compared to 1.66x for the average Healthcare stock.

At current multiples, Moderna, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Moderna, Inc. Profitability — ROE, Margins, and Quality Score

Moderna, Inc. (MRNA) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -22.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -16.1% versus the sector average of -33.1%.

On a margin basis, Moderna, Inc. reports gross margins of 46.2%, compared to 71.5% for the sector. The operating margin is -410.1% (sector: -66.1%). Net profit margin stands at -374.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 321.6% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

MRNA Debt, Balance Sheet, and Financial Health

Moderna, Inc. has a debt-to-equity ratio of 43.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.29x, indicating strong short-term liquidity. Total debt on the balance sheet is $26M. Cash and equivalents stand at $1.13B.

MRNA has a beta of 1.33, meaning it is more volatile than the broader market — a $10,000 investment in MRNA would be expected to move 32.7% more than the S&P 500 on any given day. The stability factor score for Moderna, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Moderna, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Moderna, Inc. reported revenue of $3.13B and earnings per share (EPS) of $-7.26. Net income for the quarter was $-1.98B. Gross margin was 46.2%. Operating income came in at $-2.29B.

In FY 2025, Moderna, Inc. reported revenue of $1.94B and earnings per share (EPS) of $-7.26. Net income for the quarter was $-2.82B. Gross margin was 55.4%. Revenue grew -39.9% year-over-year compared to FY 2024. Operating income came in at $-3.07B.

In Q3 2025, Moderna, Inc. reported revenue of $1.02B and earnings per share (EPS) of $-0.51. Net income for the quarter was $-200M. Gross margin was 79.6%. Revenue grew -45.4% year-over-year compared to Q3 2024. Operating income came in at $-260M.

In Q2 2025, Moderna, Inc. reported revenue of $142M and earnings per share (EPS) of $-2.13. Net income for the quarter was $-825M. Gross margin was 16.2%. Revenue grew -41.1% year-over-year compared to Q2 2024. Operating income came in at $-907M.

Over the past 8 quarters, Moderna, Inc. has demonstrated a growth trajectory, with revenue expanding from $241M to $3.13B. Investors analyzing MRNA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MRNA Dividend Yield and Income Analysis

Moderna, Inc. (MRNA) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MRNA Momentum and Technical Analysis Profile

Moderna, Inc. (MRNA) has a momentum factor score of 71/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

MRNA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Moderna, Inc. (MRNA) ranks #207 out of 838 stocks based on the Blank Capital composite score. This places MRNA in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MRNA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MRNA vs S&P 500 (SPY) comparison to assess how Moderna, Inc. stacks up against the broader market across all factor dimensions.

MRNA Next Earnings Date

No upcoming earnings date has been announced for Moderna, Inc. (MRNA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MRNA? — Investment Thesis Summary

Moderna, Inc. presents a balanced picture with arguments on both sides. The value score of 21/100 indicates premium valuation. Price momentum is positive at 71/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Moderna, Inc. (MRNA) earns a Hold rating with a composite score of 42.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MRNA stock.

Related Resources for MRNA Investors

Explore more research and tools: MRNA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MRNA head-to-head with peers: MRNA vs AZN, MRNA vs SLGL, MRNA vs VMD.